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Abstract Eglin c with mutants L45R and D42R at the P1 and
P4 positions has been reported to become a stable inhibitor
toward the proprotein convertases (PC), furin and kexin, with
a Ki of 2.3U1038 and 1.3U10310 M, respectively. The mutant
was further engineered at the P2P^P4P positions to create a more
potent and selective inhibitor for each enzyme. The residue Asp
at P1P which is crucial for stabilizing the conformation of eglin c
remained unchanged. The eglin c mutants cloned into the vector
pGEX-2T and expressed in Escherichia coli (DH5K) were puri-
¢ed to homogeneity, and their inhibitory activities toward the
puri¢ed recombinant furin and kexin were examined. The re-
sults showed that (1) Leu47 at P2P replaced with either a pos-
itively or negatively charged residue resulted in a decrease in
inhibitory activities to both enzymes; (2) the replacement of Arg
with Asp at P3P was favorable for inhibiting furin with a Ki of
7.8U1039 M, but not for inhibiting kexin; (3) the replacement
of Tyr with Glu at P4P increased the inhibitory activity to kexin
with a Ki of 3U10311 M, but was almost without any in£uence
on furin inhibition. It was indicated that the inhibitory speci¢c-
ity of eglin c could be changed from inhibiting elastase to in-
hibiting PCs by site-directed mutation at the P positions, while
the inhibitory selectivity to furin or kexin could be optimized by
mutation at the PP positions.
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1. Introduction
The processing of precursor proteins via limited proteolysis
at paired basic amino acids is an important and widely used
cellular mechanism for the generation of biologically active
proteins and peptides. The furin-like endoproteinases play
broad and important roles in the proteolytic activation of
not only most peptide hormones and neuropeptides but also
many growth factors, receptors, adhesion molecules, serum
proteins, plasma proteins and matrix metalloproteinases [1^
5]. In addition to endogenous proteins, many pathogens of
bacterial exotoxins and viral envelope glycoproteins also re-
quire these enzymes to be activated [6^11]. Kexin is the ¢rst
discovered enzyme of this proprotein convertase (PC) family
found in the yeast Saccharomyces cerevisiae [12,13]. Since then
its mammalian counterparts have also been identi¢ed in
mouse pituitary and human insulinoma as PC1/3, PC2 and
others [14,15]. Among them, furin localized in the trans-Golgi
network is ubiquitous as it is present in all tissues and cell
lines examined [16]. Because of the homology of their catalytic
domains with that of the bacterial serine protease, subtilisin,
these enzymes are also called subtilisin-like PCs [17]. Mice
with the furin gene knocked out died in the fetal period
[18]. However, the furin-de¢cient cell lines were not infected
by some viruses and exogenous pathogens [19]. In cellular and
animal studies, the engineered variant of K1-antitrypsin Port-
land (K1-PDX) was used to block PC activity and to prevent
the production of pathogenic viruses, bacterial toxin activa-
tion, and cancer metastasis [20].
Though small synthetic peptides could inhibit furin and
kexin in vitro, their toxicity limits their possible therapeutic
application [21]. It was reported that some protein inhibitors
such as K1-antitrypsin and ovomucoid were successfully engi-
neered to become inhibitors for furin [22,23]. Our previous
results showed that the eglin c variant with residues Leu
and Pro at positions P1 and P4 replaced by a basic residue
Arg (designated M1 in Table 1) exhibited a fairly strong in-
hibitory activity toward furin and kexin. If the P2 residue Thr
was also mutated to a basic residue (designated M2 in Table
1), the inhibitory activity was almost one order of magnitude
higher. However, this inhibitor was unstable and cleaved
slowly by the enzyme (temporary inhibition) [24,25]. There-
fore, we chose M1 as the starting material to be further bio-
engineered at the PP positions. According to molecular mod-
eling there are distinct di¡erences between the SP subsites of
furin and kexin, so the corresponding PP residues of their
selective inhibitors should also be di¡erent. As the P1P residue
Asp46 of eglin c plays an important role in maintaining the
stable molecular conformation, this residue was unchanged
[26]. The crystal structure of either furin or kexin has not
been solved because of the instability of these enzymes. It
would be desirable to ¢nd out a potent inhibitor and to obtain
a stable inhibitor^enzyme complex to be crystallized. In this
paper we report two engineered potent inhibitors selective for
furin or kexin.
2. Materials and methods
2.1. Materials
All restriction enzymes, Taq DNA polymerase, Wizard PCR Preps
DNA puri¢cation kit were from Promega. The GST-2T vector (glu-
tathione S-transferase fusion protein expression system), thrombin,
glutathione-Sepharose 4B and Chelating-Sepharose Fast Flow were
from Amersham Pharmacia. The £uorogenic substrate pyrArg-Thr-
Lys-Arg-MCA was from Bachem Bioscience. The pPICZ-C vector
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was from Invitrogen. Oligonucleotides were synthesized in the Shang-
hai Institute of Biochemistry and Cell Biology. The F-4010 £uores-
cence spectrophotometer was manufactured by Hitachi. The ultra¢l-
tration system was from Millipore. The gene encoding prokexin was a
gift from Dr. R.S. Fuller (University of Michigan Medical School).
The puri¢ed furin was a gift from Dr. I. Lindberg (Louisiana State
University).
2.2. Gene cloning of the eglin c variants
Site-directed mutagenesis of M1 was performed by polymerase
chain reaction (PCR). The mutated gene was cloned through the
£anking BamHI and EcoRI restriction sites into the expression vector
pGEX-2T provided by the GST kit. The nucleotide sequence of the
mutant was veri¢ed by DNA sequencing. The primer pairs for the
di¡erent mutants were as follows: RVTRDERY (M3): 5P-CGTGAC-
GAGCGTTACAA-3P, 5P-TTGTAACGCTCGTCACG-3P ; RVTRD-
RRY (M4): 5P-CGTGACCGTCGTTACAA-3P, 5P-TTGTAACGA-
CGGTCACG-3P ; RVTRDLDY (M5): 5P-CGTGACCTGGATTA-
CAA-3P, 5P-TTGTAATCCAGGTCACG-3P ; RVTRDLRR (M6): 5P-
GACCTGCGTCGCAACCG-3P, 5P-CGGTTGCGACGCAGGTC-3P ;
RVTRDLRE (M7): 5P-GACCTGCGTGAGAACCG-3P, 5P-CGGT-
TCTCACGCAGGTC-3P ; RVTRDARY (M8): 5P-CGTGACGCGC-
GTTACAA-3P, 5P-TTGTAACGCGCGTCACG-3P.
2.3. Expression and puri¢cation of eglin c variants
The expression vector was transformed into Escherichia coli strain
DH5K as described [27]. Cells were grown in LB medium containing
2% (w/v) glucose and 100 Wg/ml ampicillin until OD600 reached 0.8.
The expression of the fusion protein GST-eglin c mutant was then
induced with isopropylthiogalactoside. The harvested cells were
treated with ultrasonic wave. The fusion protein was puri¢ed by af-
¢nity chromatography with a glutathione-Sepharose 4B column. The
eluted fraction was hydrolyzed by thrombin. The eglin c variant was
puri¢ed by reverse phase high performance liquid chromatography
(HPLC) with gradient elution from 100% bu¡er A (0.1% tri£uoro-
acetic acid) to 70% bu¡er B (70% acetonitrile with 0.1% tri£uoroacetic
acid) in 50 min. The puri¢ed eglin c mutant was lyophilized for in-
hibitory activity assay.
2.4. Gene cloning and expression of the secreted soluble kexin
The kexin gene with the C-terminal 201 residues deleted was cloned
into the pPICZ-C vector using the EcoRI and XhoI restriction sites.
There were 6 His (for a⁄nity chromatography) and a c-myc sequence
at the C-terminus. The transformation of the plasmid into Pichia
pastoris and the selection of the Mutþ clones were performed as
described [28]. After induction by methanol for 72 h, the media
were pooled and ultra-¢ltered using a 10 kDa cuto¡ membrane in a
50 ml stirred cell (Millipore) and washed with 20 mM phosphate
bu¡er, pH 7.0, containing 1 mM CaCl2 and 1 M NaCl. The concen-
trated sample was applied to a Chelating-Sepharose Fast Flow a⁄nity
column and eluted with 20 mM phosphate bu¡er, pH 7.0, containing
1 mM CaCl2 and 1 M imidazole. The eluted fraction was concen-
trated using Centricon 10 (Amicon) and dialyzed against 20 mM
HEPES bu¡er, pH 7.5, containing 1 mM CaCl2 and 10% glycerol,
and stored at 370‡C.
2.5. Enzyme activity assays
The enzyme activity of furin and kexin was measured at 37‡C in a
volume of 1 ml using 1 WM or 2 WM £uorogenic MCA substrate
pyrArg-Thr-Lys-Arg-MCA in 100 mM HEPES bu¡er, pH 7.5,
1 mM CaCl2, 0.5% Triton X-100 and 1 mM L-mercaptoethanol. For
each assay an equivalent amount of enzyme was added to release 15
nM/min amino-4-methylcoumarin in the period of 2 min of enzyme
reaction. For determining the inhibitory activity, a ¢xed amount of
enzyme was ¢rst incubated with di¡erent amounts of the inhibitor at
37‡C for 5 min, the residual enzyme activity was then measured. The
incubation time required for reaching the equilibrium between enzyme
and inhibitor was estimated to be less than 5 min as all initial veloc-
ities were the same from 1 to 30 min incubation. The excitation and
emission wavelengths were 370 nm and 460 nm, respectively.
2.6. Measurement of kinetic parameter, Ki
The Ki values for furin or kexin were measured by Dixon’s plot
(1/V against I) using di¡erent concentrations of substrate [29]. Data
from three measurements were averaged and graphically analyzed
with the following equation to obtain the equilibrium inhibition con-
stant, Ki. The equilibrium equation could be simpli¢ed as follows:
v
Vmax
¼ ½S
Km þ ½S þ KmK i ½I 
v ¼ 1
a½I  þ b or
1
v
¼ a½I  þ b ð1Þ
a ¼ Km
K iWVmax½S ð2Þ
b ¼ Km þ ½S
Vmax½S ð3Þ
Km is the Michaelis constant, the substrate Km was 500 WM and 2.7
nM for furin and kexin respectively, [S] is the substrate concentration,
Vmax is the initial uninhibited rate. The abscissa of the intersection
point of lines is 3Ki.
3. Results
3.1. Expression and puri¢cation of kexin
The gene encoding kexin with 201 residues deleted from the
C-terminal part was cloned into the pPICZ-C vector and ex-
pressed in P. pastoris. After ultra¢ltration with a 10 kDa cut-
o¡ membrane, the expressed recombinant enzyme was puri-
¢ed by a⁄nity chromatography with a Chelating-Sepharose
Fast Flow column (Fig. 1). Because of the low capacity of the
column, the unbound kexin could also be found in the break-
through. The puri¢ed kexin was stored at 370‡C.
3.2. Expression and puri¢cation of eglin c variants
The synthetic gene encoding eglin c was constructed by
Table 1
Inhibition constants of the eglin variants to furin and kexin
Mutation Ki
Furin (M) Kexin (M)
M1 RVTR 2.3T0.08U1038 1.28T 0.21U10310 [24]
M2 RVKR 1.6T0.27U1039 3.8T 0.16U10311 [24]
M3 RVTRDERY 9.2T0.13U1037 3.16T 0.31U10310
M4 RVTRDRRY 3.0T0.05U1037 8.9T 0.19U1038
M5 RVTRDLDY 7.8T0.17U1039 4.3T 0.22U1039
M6 RVTRDLRR 4.7 T 0.06U1038 2.67T 0.24U1038
M7 RVTRDLRE 3.9 T 0.16U1038 3.0T 0.09U10311
M8 RVTRDARY 2.0T0.20U1038 1.36T 0.13U10310
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using preferential codon usage for E. coli [21,30]. The GST
fusion protein expression system was used for all eglin c var-
iants with a yield of around 5 mg/l. The fusion protein was
puri¢ed by one-step a⁄nity chromatography on the gluta-
thione-Sepharose 4B column, and cleaved by thrombin
(Leu-Val-Pro-Args-Gly-Ser, s indicates the site of cleavage)
upstream of the N-terminus of eglin c, resulting in a recombi-
nant Gly-Ser-eglin c. The cleaved product was puri¢ed by
HPLC using C18 column (Figs. 2 and 3).
3.3. E¡ect of PP mutation of M1 on the inhibitory activity and
selectivity for furin and kexin
Considering the di¡erence of SP subsites between furin and
kexin, the residues of eglin c mutant M1 were further engi-
neered (L47E, L47R, L47A, R48D, Y49R and Y49E) at posi-
tions PP to explore whether these PP mutations would in£u-
ence its inhibitory activity and selectivity for furin and kexin.
The determined inhibition constants Ki of the mutants are
listed in Table 1. The L47E mutation (M3) at P2P resulted
in a 40-fold decrease in inhibitory activity for furin, and a
2.5-fold decrease for kexin. The L47R mutation (M4) at the
same position had a small e¡ect on furin inhibition (13-fold
decrease) but a dramatic e¡ect (700-fold decrease) on kexin
inhibition, indicating that the neutral residue at position P2P
of eglin c was needed to interact with the enzyme. Both mu-
tations with either an acid or basic residue gave a negative
e¡ect. The acidic residue mutation showed more in£uence on
furin inhibition than on kexin inhibition, while the in£uence
of the basic residue mutation was reversed. In order to ex-
clude the possible in£uence of the steric e¡ect of the hydro-
phobic residue Leu on Ki values, this position was further
mutated with the small neutral residue Ala. The result showed
that the determined Kis of the L47A mutation (M8) were
within errors, indicating that the P2P can be replaced by an-
other neutral residue, but not by charged residues. The P3P
R48D mutation (M5) increased three-fold the binding a⁄nity
of M1 for furin, but decreased it 33-fold for kexin. Thus, M5
exhibited a high degree of selectivity for furin, its inhibitory
Fig. 1. Sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) analysis of the puri¢ed kexin. Lane 1: fraction eluted
from the activated Chelating-Sepharose Fast Flow column with 20
mM phosphate bu¡er, pH 7.0, containing 1 mM CaCl2 and 1 M
imidazole; lane 2: breakthrough from the column; lane 3: starting
material concentrated by ultra¢ltration with a 10 kDa membrane in
a 50 ml stirred cell.
Fig. 2. SDS^PAGE analysis of the puri¢ed eglin c variant. Lane 1:
the puri¢ed eglin c variant cleaved with thrombin from the fusion
protein; lane 2: the fusion protein puri¢ed with glutathione-Sephar-
ose 4B column.
Fig. 3. HPLC pro¢le of the puri¢ed fusion protein eglin-GST after enzymatic cleavage with thrombin.
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activity was close to that of the suicide inhibitor M2 with a Ki
of 7.8U1039 M. The P4P Y49R mutation (M6) decreased the
binding a⁄nity of M1 for kexin about 200-fold. In contrast,
the Y49E mutation (M7) increased the a⁄nity about four-
fold. Thus, the inhibitory activity of M7 approached that of
the suicide inhibitor M2 and became a potent and selective
inhibitor of kexin with a Ki of 3U10311 M. However, neither
Y49R nor Y49E mutations at position P4P had an obvious
in£uence on the inhibitory activity of M1 to furin.
4. Discussion
The 70 residue eglin c, isolated from the leech Hirudo me-
dicinalis, belongs to the potato I inhibitor family and inhibits
strongly human leukocyte elastase, cathepsin G, K-chymo-
trypsin, and subtilisin [31^33]. Because of its low molecule
weight, stable conformation and £exible reactive site loop,
eglin c has been successfully engineered at the P positions to
become an inhibitor of the subtilisin family enzymes. Though
a very potent inhibitor with a Ki of 1039 and 10311 M to furin
and kexin respectively was generated, the mutant was unstable
and slowly cleaved by the corresponding enzyme [24,25].
Thus, it is necessary to make further mutations at the PP
positions to create a potent, selective and stable inhibitor
for furin and kexin. It was demonstrated that in eglin c the
acid residue Asp46 at position P1P formed an electrostatic
interaction with the basic residue Arg51, playing a role like
a disul¢de bond in the Kunitz family inhibitors [26]. There-
fore, Asp46 should remain unchanged. The fact that mutant
M5 (R48D) showed a higher inhibitory activity to furin but
was unfavorable for kexin inhibition could be explained by
the molecular modeling of the furin^eglin complex [34]. The
P3P residue Asp48 of eglin c is close to the S3P residue possibly
either Lys242 or His257 of furin, forming an electrostatic
interaction. In kexin this acid residue Asp48 is neighboring
to Asp80 of the enzyme, so the electrostatic repulsion between
these residues is unfavorable for forming an enzyme^inhibitor
complex. In M7, the P4P residue Glu49 could also form an
electrostatic interaction with His250 of kexin. Thus, M5 and
M7 turned out to be potent and selective inhibitors for furin
and kexin, respectively. Their inhibitory activities are almost
equivalent to that of the suicide inhibitor M2 mutated only at
the P positions [24,25]. However, unlike M2, they are stable
and not cleaved by their corresponding enzymes.
Naturally occurring inhibitors for PCs have not been found
yet. Until now several protein inhibitors of PCs have been
reported such as the engineered ovomucoid third domain in-
hibitor, K1-PDX, and eglin c variants [22^25,35]. The e¡ective
inhibition of PCs by K1-PDX in vivo has been con¢rmed both
by expressing the K1-PDX gene in the target cells and by
adding the puri¢ed K1-PDX to tissue culture media
[23,36,37]. However, the large size (V400 amino acids) and
relative instability of the serpin family inhibitor may hamper
the potential therapeutic application. The eglin variant M5 for
furin inhibition reported in this paper may have more advan-
tages because of its low molecule weight and stability.
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